CN114057823B - 白桦脂酸衍生物，其制备方法、药物组合物和应用 - Google Patents
白桦脂酸衍生物，其制备方法、药物组合物和应用 Download PDFInfo
- Publication number
- CN114057823B CN114057823B CN202010785694.XA CN202010785694A CN114057823B CN 114057823 B CN114057823 B CN 114057823B CN 202010785694 A CN202010785694 A CN 202010785694A CN 114057823 B CN114057823 B CN 114057823B
- Authority
- CN
- China
- Prior art keywords
- compound
- betulinic acid
- acid derivative
- ynyl
- enyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical class C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 title claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 65
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 5
- 239000003054 catalyst Substances 0.000 claims description 5
- 229940125904 compound 1 Drugs 0.000 claims description 4
- 229940125782 compound 2 Drugs 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000005907 cancer growth Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 8
- 229940002612 prodrug Drugs 0.000 abstract description 4
- 239000000651 prodrug Substances 0.000 abstract description 4
- 238000001308 synthesis method Methods 0.000 abstract description 2
- -1 triterpene compound Chemical class 0.000 description 94
- 238000005481 NMR spectroscopy Methods 0.000 description 31
- 125000000217 alkyl group Chemical group 0.000 description 29
- 125000003118 aryl group Chemical group 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 125000004432 carbon atom Chemical group C* 0.000 description 20
- 125000000623 heterocyclic group Chemical group 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 229910052739 hydrogen Inorganic materials 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 13
- 239000001257 hydrogen Substances 0.000 description 13
- 239000007787 solid Substances 0.000 description 12
- 238000001228 spectrum Methods 0.000 description 11
- 125000002619 bicyclic group Chemical group 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 229910052736 halogen Inorganic materials 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- 150000002430 hydrocarbons Chemical group 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 description 5
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 150000001924 cycloalkanes Chemical class 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 description 4
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 230000036436 anti-hiv Effects 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 2
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 2
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- JUSWZYFYLXTMLJ-JTQLQIEISA-N (2s)-1-(benzenesulfonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1S(=O)(=O)C1=CC=CC=C1 JUSWZYFYLXTMLJ-JTQLQIEISA-N 0.000 description 1
- RQYKQWFHJOBBAO-JTQLQIEISA-N (2s)-1-benzoylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)C1=CC=CC=C1 RQYKQWFHJOBBAO-JTQLQIEISA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- SPZFCKVVHXRLAI-XOCWCZJOSA-N (3s,4s)-4-[8-[[(1r,3as,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carbonyl]amino]octanoylamino]-3-hydroxy-6-methylheptanoic acid Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@@H]2[C@H]3[C@H](C(C)=C)CC[C@]3(C(=O)NCCCCCCCC(=O)N[C@@H](CC(C)C)[C@@H](O)CC(O)=O)CC[C@]21C SPZFCKVVHXRLAI-XOCWCZJOSA-N 0.000 description 1
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- FHPJZSIIXUQGQE-JVZYCSMKSA-N 1-[(2r,3r,4s,5r)-5-azido-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@@H]1[C@H](O)[C@](CO)(N=[N+]=[N-])O[C@H]1N1C(=O)NC(=O)C=C1 FHPJZSIIXUQGQE-JVZYCSMKSA-N 0.000 description 1
- XXFUZSHTIOFGNV-UHFFFAOYSA-N 1-bromoprop-1-yne Chemical compound CC#CBr XXFUZSHTIOFGNV-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- GOCCREQJUBABAL-UHFFFAOYSA-N 2,2-dihydroxyacetic acid Chemical compound OC(O)C(O)=O GOCCREQJUBABAL-UHFFFAOYSA-N 0.000 description 1
- UZYQSNQJLWTICD-UHFFFAOYSA-N 2-(n-benzoylanilino)-2,2-dinitroacetic acid Chemical compound C=1C=CC=CC=1N(C(C(=O)O)([N+]([O-])=O)[N+]([O-])=O)C(=O)C1=CC=CC=C1 UZYQSNQJLWTICD-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-L D-glucarate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O DSLZVSRJTYRBFB-LLEIAEIESA-L 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical class CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-O Methylammonium ion Chemical compound [NH3+]C BAVYZALUXZFZLV-UHFFFAOYSA-O 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- KQZVSTAVTJCKDG-DRSBITMPSA-N [2-amino-3-hydroxy-2-(hydroxymethyl)propyl] (1r,3as,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-9-acetyloxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylate Chemical compound C([C@]1(CC[C@H]([C@@H]1[C@H]1CC[C@H]23)C(C)=C)C(=O)OCC(N)(CO)CO)C[C@@]1(C)[C@]3(C)CC[C@@H]1[C@]2(C)CC[C@H](OC(=O)C)C1(C)C KQZVSTAVTJCKDG-DRSBITMPSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000005108 alkenylthio group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- 125000005109 alkynylthio group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-O benzylaminium Chemical compound [NH3+]CC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-O 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- YJEJKUQEXFSVCJ-WRFMNRASSA-N bevirimat Chemical compound C1C[C@H](OC(=O)CC(C)(C)C(O)=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C YJEJKUQEXFSVCJ-WRFMNRASSA-N 0.000 description 1
- 229950002892 bevirimat Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- VEWFZHAHZPVQES-UHFFFAOYSA-N boron;n,n-diethylethanamine Chemical compound [B].CCN(CC)CC VEWFZHAHZPVQES-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KTUQUZJOVNIKNZ-UHFFFAOYSA-N butan-1-ol;hydrate Chemical compound O.CCCCO KTUQUZJOVNIKNZ-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical class CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000004465 cycloalkenyloxy group Chemical group 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000005366 cycloalkylthio group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-O dicyclohexylazanium Chemical compound C1CCCCC1[NH2+]C1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-O 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-O diethylammonium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-O ethylaminium Chemical compound CC[NH3+] QUSNBJAOOMFDIB-UHFFFAOYSA-O 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical class C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000005368 heteroarylthio group Chemical group 0.000 description 1
- 125000004468 heterocyclylthio group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-O isopropylaminium Chemical compound CC(C)[NH3+] JJWLVOIRVHMVIS-UHFFFAOYSA-O 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N itaconic acid Chemical compound OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000013379 physicochemical characterization Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-O propan-1-aminium Chemical compound CCC[NH3+] WGYKZJWCGVVSQN-UHFFFAOYSA-O 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
- 125000004497 pyrazol-5-yl group Chemical group N1N=CC=C1* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical class CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000005556 thienylene group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于医药领域，具体提供一种式(I)所示的白桦脂酸衍生物，其药学上可接受的盐、水合物或前药：本发明还提供所述白桦脂酸衍生物的药物组合物、合成方法和应用。
Description
技术领域
本发明属于医药领域，具体涉及白桦脂酸衍生物，其制备方法、药物组合物和应用。
背景技术
白桦脂酸(Betulinic acid,BA)是一种五环三萜类化合物，存在于白桦树、夏枯草、木瓜等多种植物中。研究发现，已有部分白桦脂酸衍生物展示出一定的抗病毒、抗肿瘤或抗炎效用，如RPR103611和PA457(bevirimat)已经处于抗HIV的临床实验阶段，NVX-207在进行抗肿瘤的临床实验。但是，仍需不断开发具有改善活性的白桦脂酸衍生物。
发明内容
为改善上述技术问题，本发明提供一种式(I)所示的白桦脂酸衍生物，其药学上可接受的盐、互变异构体、立体异构体、氮氧化物、水合物或前药：
其中，X选自O、无取代或任选被一个、两个或更多个Ra取代的下列基团：C1-40烷基、NH；
R1选自H、无取代或任选被一个、两个或更多个Rb取代的下列基团：C1-40烷基、C3-20环烷基、3-20元杂环基、C6-20芳基或5-20元杂芳基；
Het1选自被1个、2个或更多个Rm取代的5-6元杂环基，例如
Het2选自被1个、2个或更多个Rn取代的
Het1通过其成环的碳原子或氮原子与Het2中的成环碳原子或氮原子键合；
Het1通过其成环的碳原子或氮原子基团与三氮唑基团的N原子键合；
Y选自H、卤素、OH、SH、CN、OH，无取代或任选被一个、两个或更多个Rc取代的下列基团：C1-40烷基、C3-20环烷基、C1-40烷氧基、3-20元杂环基、C6-20芳基、5-20元杂芳基、3-20元杂环基氧基、C6-20芳基氧基、5-20元杂芳基氧基、NH2、-C(O)OR3、-OC(O)R4、-OP(O)(OR5)2、-OS(O)2R6；
Z选自O、S、卤素、OH、SH、CN、无取代或任选被一个、两个或更多个Rd取代的下列基团：C1-40烷基、C3-20环烷基、C1-40烷氧基、3-20元杂环基、C6-20芳基、5-20元杂芳基、3-20元杂环基氧基、C6-20芳基氧基、5-20元杂芳基氧基、NH2、-C(O)OR2、-OC(O)R3、-OP(O)(OR4)2、-OS(O)2R5；其中，当为双键时，Z选自O或S；当/>为单键时，Z选自上文定义的除O和S之外的其他基团；
每一个R3、R4、R5、R6相同或不同，彼此独立地选自H、无取代或任选被一个、两个或更多个Re取代的下列基团：C1-40烷基、C3-20环烷基、3-20元杂环基、C6-20芳基、5-20元杂芳基；
Rm、Rn相同或不同，彼此独立地选自H、卤素、OH、SH、CN，无取代或任选被一个、两个或更多个Rf取代的下列基团：C1-40烷基或C1-40烷氧基；
Ra、Rb、Rc、Rd、Re、Rf相同或不同，彼此独立地选自卤素、OH、CN、NO2、氧代(＝O)、硫代(＝S)、C1-40烷基、C2-40烯基、C2-40炔基、C3-40环烷基、C3-40环烯基、C3-40环炔基、C6-20芳基、5-20元杂芳基、3-20元杂环基、C1-40烷基氧基、C2-40烯基氧基、C2-40炔基氧基、C3-40环烷基氧基、C3-40环烯基氧基、C3-40环炔基氧基、C6-20芳基氧基、5-20元杂芳基氧基、3-20元杂环基氧基、C1-40烷基硫基、C2-40烯基硫基、C2-40炔基硫基、C3-40环烷基硫基、C3-40环烯基硫基、C3-40环炔基硫基、C6-20芳基硫基、5-20元杂芳基硫基、3-20元杂环基硫基、NH2、-C(O)C1-40烷基、-C(O)NH2、-C(O)NHC1-40烷基、-C(O)-NH-OH、-COOC1-40烷基、-COOH、-OC(O)C1-40烷基、-OC(O)H、-S(O)2C1-40烷基、S(O)2H、-S(O)2OC1-40烷基、-OS(O)2C1-40烷基、-P(O)(OH)2、-B(OH)2。
根据本发明的实施方案，所述白桦脂酸衍生物具有式(I-1)或式(I-2)所示的结构：
其中，X选自O、无取代或任选被一个、两个或更多个Ra取代的NH或CH2；
R选自H、C1-6烷基、C3-8环烷基；
R1选自H、无取代或任选被一个、两个或更多个Rb取代的下列基团：C1-6烷基、C3-8环烷基、3-8元杂环基、C6-14芳基或5-14元杂芳基；
R2选自H、卤素、OH、SH、CN，无取代或任选被一个、两个或更多个Rf取代的下列基团：C1-6烷基或C1-6烷氧基；
Z选自O、卤素、OH、SH、CN、无取代或任选被一个、两个或更多个Rd取代的C1-6烷基或C1-6烷氧基，当为双键时，Z选自O；当/>为单键时，Z选自上文定义的除O之外的其他基团；
Ra选自C1-6烷基；
Rb、Rf相同或不同，彼此独立地选自卤素、OH、CN、NO2、C1-6烷基、C3-8环烷基、C1-6烷氧基、3-8元杂环基、C6-14芳基、5-14元杂芳基、3-8元杂环基氧基、C6-14芳基氧基或5-14元杂芳基氧基。
根据本发明的实施方案，所述白桦脂酸衍生物具有式(I-3)或式(I-4)所示的结构：
其中，X选自O；
R选自H、C1-6烷基；
R1选自H或C1-6烷基；
R2选自H、F、Cl、Br、OH、SH、CN或CH3；
Z选自O、F、Cl、Br、OH、CN、C1-6烷基或C1-6烷氧基，当为双键时，Z为O；当/>为单键时，Z选自F、Cl、Br、OH、CN、C1-6烷基或C1-6烷氧基。
作为实例，所述白桦脂酸衍生物选自如下化合物：
本发明还提供所述白桦脂酸衍生物的制备方法，包括将式(1)化合物与式(2)化合物反应，得到式(I)所示的白桦脂酸衍生物：
其中，R1、Het1、Het2、X、Z、独立地具有上文所述的定义。
根据本发明的实施方案，所述反应可以在溶剂中进行；所述溶剂可以为水与有机溶剂的混合溶剂；所述有机溶剂可以为甲醇、乙醇、异丙醇、正丁醇、叔丁醇、四氢呋喃、二氧六环、N,N-二甲基甲酰胺；
根据本发明的实施方案，所述水与有机溶剂的体积比为1:0.2-5，例如1:0.5-3，示例性为1:1；
根据本发明的实施方案，所述反应在催化剂存在下进行，所述催化剂在反应过程中会形成一价铜离子，例如为Cu和CuSO4的组合、CuCl、CuI；
根据本发明的实施方案，所述反应中化合物1与催化剂的摩尔比为1:0.1-1，例如为1:0.2-0.8；
根据本发明的实施方案，所述反应中化合物1与化合物2的摩尔比为1:0.5-2，例如为1:0.8-1.2。
本发明还提供一种药物组合物，其包含治疗有效量的所述白桦脂酸衍生物、其药学上可接受的盐、互变异构体、立体异构体、氮氧化物、水合物或前药。
根据本发明的实施方案，所述药物组合物还包括一种或多种药学上可接受的辅料，例如载体或赋形剂。
根据本发明的实施方案，所述药物组合物还可以进一步含有或不含有一种或多种额外的治疗剂。
根据本发明的实施方案，所述药物组合物还包括赋形剂，通过所述赋形剂将药物组合物稀释或装入例如胶囊、小药囊、纸或其它容器形式的这种载体内。当赋形剂用作稀释剂时，它可以是固体、半固体或液体物质，用作溶媒、载体或活性成分的介质。因此，所述药物组合物可以是以下形式：片剂、丸剂、散剂、锭剂、小药囊、扁囊剂、酏剂、混悬剂、乳剂、溶液剂、糖浆剂、气雾剂(固体或溶于液体溶媒)；例如含高达10％重量活性成分的软膏剂、软和硬明胶胶囊、栓剂、无菌注射溶液和无菌包装粉末。
优选地，所述适宜赋形剂选自乳糖、葡萄糖、蔗糖、山梨醇、甘露醇、淀粉、阿拉伯胶、磷酸钙、藻酸盐、黄蓍胶、明胶、硅酸钙、微晶纤维素、聚乙烯吡咯烷酮、纤维素、水、糖浆和甲基纤维素。
本发明还提供所述白桦脂酸衍生物，其药学上可接受的盐、互变异构体、立体异构体、氮氧化物、水合物或前药在制备药物中的用途，其中所述药物为抗肿瘤药物或抗病毒药物。
根据本发明的实施方案，所述肿瘤为癌。
根据本发明的实施方案，所述病毒为HIV病毒。
根据本发明的实施方案，所述药物可以用于抑制肿瘤细胞生长，所述肿瘤细胞可以为癌细胞，如选自宫颈癌细胞、肺腺癌细胞、乳腺癌细胞、肝癌细胞、食道癌细胞，其实例可以为选自下列的细胞：Hela、C33a、Siha、A549、MCF-7、LUC7721、HEPG2、SK-BR-3、KYSE150。
本发明还提供一种预防或治疗肿瘤(例如癌症)或病毒(如HIV)感染的方法，包括向有此需要的患者施用治疗有效量的所述白桦脂酸衍生物，其药学上可接受的盐、互变异构体、立体异构体、氮氧化物、水合物或前药。
根据本发明的实施方案，所述癌症可以为宫颈癌、肺腺癌、乳腺癌、肝癌、食道癌。
有益效果
发明人意外地发现，本发明提供的化合物具有优异的抗肿瘤活性和抗病毒活性。并且，本发明提供合成方法简便可行，收率较高，将其应用于制备抗肿瘤的药物，具有较好的应用价值。
附图说明
图1为化合物2的核磁共振氢谱；
图2为化合物3的核磁共振氢谱；
图3为化合物4的核磁共振氢谱；
图4为化合物5的核磁共振氢谱；
图5为化合物6的核磁共振氢谱；
图6为化合物i的核磁共振氢谱；
图7为化合物ii的核磁共振氢谱；
图8为化合物iii的核磁共振氢谱；
图9为化合物i的高分辨质谱；
图10为化合物ii的高分辨质谱；
图11为化合物iii的高分辨质谱；
图12为化合物iv的核磁共振氢谱；
图13为化合物v的核磁共振氢谱；
图14为化合物vi的核磁共振氢谱；
图15为化合物iv的高分辨质谱；
图16为化合物v的高分辨质谱；
图17为化合物vi的高分辨质谱。
术语定义与说明
除非另有说明，本申请说明书和权利要求书中记载的基团和术语定义，包括其作为实例的定义、示例性的定义、优选的定义、表格中记载的定义、实施例中具体化合物的定义等，可以彼此之间任意组合和结合。这样的组合和结合后的基团定义及化合物结构，应当属于本申请说明书记载的范围内。
除非另有说明，本说明书和权利要求书记载的数值范围相当于至少记载了其中每一个具体的整数数值。例如，数值范围“1-40”相当于记载了数值范围“1-10”中的每一个整数数值即1、2、3、4、5、6、7、8、9、10，以及数值范围“11-40”中的每一个整数数值即11、12、13、14、15、......、35、36、37、38、39、40。此外，当某些数值范围被定义为“数”时，应当理解为记载了该范围的两个端点、该范围内的每一个整数以及该范围内的每一个小数。例如，“0～10的数”应当理解为不仅记载了0、1、2、3、4、5、6、7、8、9和10的每一个整数，还至少记载了其中每一个整数分别与0.1、0.2、0.3、0.4、0.5、0.6、0.7、0.8、0.9的和。
应当理解，本文在描述1、2个或更多个中，“更多个”应当是指大于2，例如大于等于3的整数，例如3、4、5、6、7、8、9或10。
术语“卤素”表示氟、氯、溴和碘。
术语“C1-40烷基”应理解为表示具有1～40个碳原子的直链或支链饱和一价烃基。例如，“C1-6烷基”表示具有1、2、3、4、5或6个碳原子的直链和支链烷基。所述烷基是例如甲基、乙基、丙基、丁基、戊基、己基、异丙基、异丁基、仲丁基、叔丁基、异戊基、2-甲基丁基、1-甲基丁基、1-乙基丙基、1,2-二甲基丙基、新戊基、1,1-二甲基丙基、4-甲基戊基、3-甲基戊基、2-甲基戊基、1-甲基戊基、2-乙基丁基、1-乙基丁基、3,3-二甲基丁基、2,2-二甲基丁基、1,1-二甲基丁基、2,3-二甲基丁基、1,3-二甲基丁基或1,2-二甲基丁基等或它们的异构体。
术语“C2-40烯基”应理解为优选表示直连或支链的一价烃基，其包含一个或多个双键并且具有2～40个碳原子，优选“C2-10烯基”。“C2-10烯基”应理解为优选表示直连或支链的一价烃基，其包含一个或多个双键并且具有2、3、4、5、6、7、8、9或10个碳原子，例如，具有2、3、4、5或6个碳原子(即，C2-6烯基)，具有2或3个碳原子(即，C2-3烯基)。应理解，在所述烯基包含多于一个双键的情况下，所述双键可相互分离或者共轭。所述烯基是例如乙烯基、烯丙基、(E)-2-甲基乙烯基、(Z)-2-甲基乙烯基、(E)-丁-2-烯基、(Z)-丁-2-烯基、(E)-丁-1-烯基、(Z)-丁-1-烯基、戊-4-烯基、(E)-戊-3-烯基、(Z)-戊-3-烯基、(E)-戊-2-烯基、(Z)-戊-2-烯基、(E)-戊-1-烯基、(Z)-戊-1-烯基、己-5-烯基、(E)-己-4-烯基、(Z)-己-4-烯基、(E)-己-3-烯基、(Z)-己-3-烯基、(E)-己-2-烯基、(Z)-己-2-烯基、(E)-己-1-烯基、(Z)-己-1-烯基、异丙烯基、2-甲基丙-2-烯基、1-甲基丙-2-烯基、2-甲基丙-1-烯基、(E)-1-甲基丙-1-烯基、(Z)-1-甲基丙-1-烯基、3-甲基丁-3-烯基、2-甲基丁-3-烯基、1-甲基丁-3-烯基、3-甲基丁-2-烯基、(E)-2-甲基丁-2-烯基、(Z)-2-甲基丁-2-烯基、(E)-1-甲基丁-2-烯基、(Z)-1-甲基丁-2-烯基、(E)-3-甲基丁-1-烯基、(Z)-3-甲基丁-1-烯基、(E)-2-甲基丁-1-烯基、(Z)-2-甲基丁-1-烯基、(E)-1-甲基丁-1-烯基、(Z)-1-甲基丁-1-烯基、1,1-二甲基丙-2-烯基、1-乙基丙-1-烯基、1-丙基乙烯基、1-异丙基乙烯基。
术语“C2-40炔基”应理解为表示直连或支链的一价烃基，其包含一个或多个三键并且具有2～40个碳原子，优选“C2-10炔基”。术语“C2-10炔基”应理解为优选表示直连或支链的一价烃基，其包含一个或多个三键并且具有2、3、4、5、6、7、8、9或10个碳原子，，例如，具有2、3、4、5或6个碳原子(即，“C2-6炔基”)，具有2或3个碳原子(“C2-3炔基”)。所述炔基是例如乙炔基、丙-1-炔基、丙-2-炔基、丁-1-炔基、丁-2-炔基、丁-3-炔基、戊-1-炔基、戊-2-炔基、戊-3-炔基、戊-4-炔基、己-1-炔基、己-2-炔基、己-3-炔基、己-4-炔基、己-5-炔基、1-甲基丙-2-炔基、2-甲基丁-3-炔基、1-甲基丁-3-炔基、1-甲基丁-2-炔基、3-甲基丁-1-炔基、1-乙基丙-2-炔基、3-甲基戊-4-炔基、2-甲基戊-4-炔基、1-甲基戊-4-炔基、2-甲基戊-3-炔基、1-甲基戊-3-炔基、4-甲基戊-2-炔基、1-甲基戊-2-炔基、4-甲基戊-1-炔基、3-甲基戊-1-炔基、2-乙基丁-3-炔基、1-乙基丁-3-炔基、1-乙基丁-2-炔基、1-丙基丙-2-炔基、1-异丙基丙-2-炔基、2,2-二甲基丁-3-炔基、1,1-二甲基丁-3-炔基、1,1-二甲基丁-2-炔基或3,3-二甲基丁-1-炔基。特别地，所述炔基是乙炔基、丙-1-炔基或丙-2-炔基。
术语“C3-20环烷基”应理解为表示饱和的一价单环、双环烃环或桥环烷烃，其具有3～20个碳原子，优选“C3-10环烷基”。术语“C3-10环烷基”应理解为表示饱和的一价单环、双环烃环或桥环烷烃，其具有3、4、5、6、7、8、9或10个碳原子。所述C3-10环烷基可以是单环烃基，如环丙基、环丁基、环戊基、环己基、环庚基、环辛基、环壬基或环癸基，或者是双环烃基如十氢化萘环。
术语“3-20元杂环基”意指饱和的一价单环、双环烃环或桥环烷烃，其包含1-5个独立选自N、O和S的杂原子的总成环原子数为3-20(如原子数为3、4、5、6、7、8、9、10等)的非芳族环状基团，优选“3-10元杂环基”。术语“3-10元杂环基”意指饱和的一价单环、双环烃环或桥环烷烃，其包含1-5个，优选1-3个选自N、O和S的杂原子。所述杂环基可以通过所述碳原子中的任一个或氮原子(如果存在的话)与分子的其余部分连接。特别地，所述杂环基可以包括但不限于：4元环，如氮杂环丁烷基、氧杂环丁烷基；5元环，如四氢呋喃基、二氧杂环戊烯基、吡咯烷基、咪唑烷基、吡唑烷基、吡咯啉基；或6元环，如四氢吡喃基、哌啶基、吗啉基、二噻烷基、硫代吗啉基、哌嗪基或三噻烷基；或7元环，如二氮杂环庚烷基。任选地，所述杂环基可以是苯并稠合的。所述杂环基可以是双环的，例如但不限于5,5元环，如六氢环戊并[c]吡咯-2(1H)-基环，或者5,6元双环，如六氢吡咯并[1,2-a]吡嗪-2(1H)-基环。含氮原子的环可以是部分不饱和的，即它可以包含一个或多个双键，例如但不限于2,5-二氢-1H-吡咯基、4H-[1,3,4]噻二嗪基、4,5-二氢恶唑基或4H-[1,4]噻嗪基，或者，它可以是苯并稠合的，例如但不限于二氢异喹啉基。根据本发明，所述杂环基是无芳香性的。所述3-20元杂环基与其它基团相连构成本发明的化合物时，可以为3-20元杂环基上的碳原子与其它基团相连，也可以为3-20元杂环基环上杂环原子与其它基团相连。例如当3-20元杂环基选自哌嗪基时，可以为哌嗪基上的氮原子与其它基团相连。或当3-20元杂环基选自哌啶基时，可以为哌啶基环上的氮原子和其对位上的碳原子与其它基团相连。
术语“C6-20芳基”应理解为优选表示具有6～20个碳原子的一价芳香性或部分芳香性的单环、双环或三环烃环，优选“C6-14芳基”。术语“C6-14芳基”应理解为优选表示具有6、7、8、9、10、11、12、13或14个碳原子的一价芳香性或部分芳香性的单环、双环或三环烃环(“C6-14芳基”)，特别是具有6个碳原子的环(“C6芳基”)，例如苯基；或联苯基，或者是具有9个碳原子的环(“C9芳基”)，例如茚满基或茚基，或者是具有10个碳原子的环(“C10芳基”)，例如四氢化萘基、二氢萘基或萘基，或者是具有13个碳原子的环(“C13芳基”)，例如芴基，或者是具有14个碳原子的环(“C14芳基”)，例如蒽基。当所述C6-20芳基被取代时，其可以为单取代或者多取代。并且，对其取代位点没有限制，例如可以为邻位、对位或间位取代。
术语“5-20元杂芳基”应理解为包括这样的一价单环、双环或三环芳族环系：其具有5～20个环原子且包含1-5个独立选自N、O和S的杂原子，例如“5-14元杂芳基”。术语“5-14元杂芳基”应理解为包括这样的一价单环、双环或三环芳族环系：其具有5、6、7、8、9、10、11、12、13或14个环原子，特别是5或6或9或10个碳原子，且其包含1-5个，优选1-3各独立选自N、O和S的杂原子并且，另外在每一种情况下可为苯并稠合的。特别地，杂芳基选自噻吩基、呋喃基、吡咯基、恶唑基、噻唑基、咪唑基、吡唑基、异恶唑基、异噻唑基、恶二唑基、三唑基、噻二唑基、噻-4H-吡唑基等以及它们的苯并衍生物，例如苯并呋喃基、苯并噻吩基、苯并恶唑基、苯并异恶唑基、苯并咪唑基、苯并三唑基、吲唑基、吲哚基、异吲哚基等；或吡啶基、哒嗪基、嘧啶基、吡嗪基、三嗪基等，以及它们的苯并衍生物，例如喹啉基、喹唑啉基、异喹啉基等；或吖辛因基、吲嗪基、嘌呤基等以及它们的苯并衍生物；或噌啉基、酞嗪基、喹唑啉基、喹喔啉基、萘啶基、蝶啶基、咔唑基、吖啶基、吩嗪基、吩噻嗪基、吩恶嗪基等。当所述5-20元杂芳基与其它基团相连构成本发明的化合物时，可以为5-20元杂芳基环上的碳原子与其它基团相连，也可以为5-20元杂芳基环上的杂原子与其它基团相连。当所述5-20元杂芳基被取代时，其可以为单取代或者多取代。并且，对其取代位点没有限制，例如可以为杂芳基环上与碳原子相连的氢被取代，或者杂芳基环上与杂原子相连的氢被取代。
除非另有说明，杂环基、杂芳基或亚杂芳基包括其所有可能的异构形式，例如其位置异构体。因此，对于一些说明性的非限制性实例，可以包括在其1-、2-、3-、4-、5-、6-、7-、8-、9-、10-、11-、12-位等(如果存在)中的一个、两个或更多个位置上取代或与其他基团键合的形式，包括吡啶-2-基、亚吡啶-2-基、吡啶-3-基、亚吡啶-3-基、吡啶-4-基和亚吡啶-4-基；噻吩基或亚噻吩基包括噻吩-2-基、亚噻吩-2-基、噻吩-3-基和亚噻吩-3-基；吡唑-1-基、吡唑-3-基、吡唑-4-基、吡唑-5-基。
除非另有说明，本文中术语的定义同样适用于包含该术语的基团，例如C1-40烷基的定义也适用于C1-40烷氧基等。
本领域技术人员可以理解，式I所示化合物可以以各种药学上可接受的盐的形式存在。如果这些化合物具有碱性中心，则其可以形成酸加成盐；如果这些化合物具有酸性中心，则其可以形成碱加成盐；如果这些化合物既包含酸性中心(例如羧基)又包含碱性中心(例如氨基)，则其还可以形成内盐。酸加成盐包括但不限于：盐酸盐、氢氟酸盐、氢溴酸盐、氢碘酸盐、硫酸盐、焦硫酸盐、磷酸盐、硝酸盐、甲磺酸盐、乙磺酸盐、2-羟基乙磺酸盐、苯磺酸盐、甲苯磺酸盐、氨基磺酸盐、2-萘磺酸盐、甲酸盐、乙酰乙酸、丙酮酸、月硅酸酯、肉桂酸酯、苯甲酸盐、醋酸盐、二羟乙酸盐、三氟乙酸盐、三甲基乙酸盐、丙酸盐、丁酸盐、己酸盐、庚酸盐、十一酸盐、硬脂酸盐、抗坏血酸盐、樟脑酸盐、樟脑磺酸盐、柠檬酸盐、富马酸盐、苹果酸盐、马来酸盐、羟基马来酸盐、草酸盐、水杨酸盐、琥珀酸盐、葡萄糖酸盐、奎尼酸盐、双羟萘酸盐、甘醇酸盐、酒石酸盐、乳酸盐、2-(4-羟基苯甲酰基)苯甲酸盐、环戊烷丙酸盐、二葡糖酸盐、3-羟基-2-萘甲酸盐、烟酸盐、扑酸盐、果胶酯酸盐、3-苯基丙酸盐、苦味酸盐、特戊酸盐、衣康酸盐、三氟甲磺酸盐、十二烷基硫酸盐、对甲苯磺酸盐、萘二磺酸盐、丙二酸盐、己二酸盐、藻酸盐、扁桃酸盐、葡庚酸盐、甘油磷酸盐、磺基水杨酸盐、半硫酸或硫氰酸盐、天冬氨酸盐等；碱加成盐例如碱金属盐、碱土金属盐和铵盐等，具体包括但不限于：钠盐、锂盐、钾盐、铵盐、铝盐、镁盐、钙盐、钡盐、铁盐、亚铁盐、锰盐、亚锰盐、锌盐、铵盐(包括与NH3和有机胺形成的盐(NH4盐)、甲铵盐、三甲铵盐、二乙铵盐、三乙铵盐、丙铵盐、三丙铵盐、异丙铵盐、叔丁铵盐、N,N'-二苄基乙二铵盐、二环己铵盐、1,6-己二铵盐、苄铵盐、乙醇铵盐、N,N-二甲基乙醇铵盐、N,N-二乙基乙醇铵盐、三乙醇铵盐、氨丁三醇盐、赖氨酸盐、精氨酸盐、组氨酸盐、葡糖铵盐、N-甲基葡糖铵盐、二甲基葡糖铵盐、乙基葡糖铵盐、葡甲铵盐、甜菜碱盐、咖啡因盐、氯普鲁卡因盐、普鲁卡因盐、利多卡因盐、吡啶盐、甲基吡啶盐、哌啶盐、吗啉盐、哌嗪盐、嘌呤盐、可可碱盐、胆碱盐)等。
根据其分子结构，本发明的化合物是手性的，因此可能存在各种对映异构体形式。因而这些化合物可以以消旋体形式或光学活性形式存在。本发明的化合物或其中间体可以通过本领域技术人员公知的化学或物理方法分离为对映异构体化合物，或者以此形式用于合成。在外消旋的胺的情况中，通过与光学活性的拆分试剂反应，从混合物制得非对映异构体。适当的拆分试剂的示例是光学活性的酸，例如R和S形式的酒石酸、二乙酰酒石酸、二苯甲酰酒石酸、扁桃酸、苹果酸、乳酸、适当的N-保护的氨基酸(例如N-苯甲酰脯氨酸或N-苯磺酰基脯氨酸)或各种光学活性的樟脑磺酸。借助光学活性的拆分试剂(例如固定在硅胶上的二硝基苯甲酰基苯基甘氨酸、三乙酸纤维素或其它碳水化合物的衍生物或手性衍生化的异丁烯酸酯聚合物)，也可有利地进行色谱对映体拆分。用于此目的的适当的洗脱剂是含水或含醇的溶剂混合物，例如，己烷/异丙醇/乙腈。
术语“互变异构体”(tautomerism)包括本领域技术人员已知的那些互变异构形式，例如选自烯醇式-酮式、酰胺式-亚胺酸式、内酰胺式-内酰亚胺式、烯胺式-亚胺烯胺式-烯胺式等的互变异构体。
可以根据已知的方法，例如通过萃取、过滤或柱层析来分离相应的稳定异构体。
术语“患者”是指包括哺乳动物在内的任何动物，优选小鼠、大鼠、其它啮齿类动物、兔、狗、猫、猪、牛、羊、马或灵长类动物，最优选人。
本文中使用的短语“治疗有效量”是指研究人员、兽医、医师或其它临床医师正在组织、系统、动物、个体或人中寻找的引起生物学或医学反应的活性化合物或药物的量，它包括以下一项或多项：(1)预防疾病：例如在易感染疾病、紊乱或病症但尚未经历或出现疾病病理或症状的个体中预防疾病、紊乱或病症。(2)抑制疾病：例如在正经历或出现疾病、紊乱或病症的病理或症状的个体中抑制疾病、紊乱或病症(即阻止病理和/或症状的进一步发展)。(3)缓解疾病：例如在正经历或出现疾病、紊乱或病症的病理或症状的个体中缓解疾病、紊乱或病症(即逆转病理和/或症状)。
具体实施方式
下文将结合具体实施例对本发明的技术方案做更进一步的详细说明。应当理解，下列实施例仅为示例性地说明和解释本发明，而不应被解释为对本发明保护范围的限制。凡基于本发明上述内容所实现的技术均涵盖在本发明旨在保护的范围内。
除非另有说明，以下实施例中使用的原料和试剂均为市售商品，或者可以通过已知方法制备。
实施例1：化合物i的制备
化合物2的合成：1000mL三口瓶中，加入白桦脂醇(20.0g，45.2mmol)和丙酮(400mL)，然后在冰浴下滴加新制备的琼斯试剂(100mL)，在冰浴下继续反应30分钟后撤去冰浴，室温搅拌8h，加入甲醇(250mL)和水(250mL)终止反应，蒸干溶剂，加入水，用乙酸乙酯萃取，合并有机相，干燥浓缩，柱色谱分离，得到白色固体2(12.2g，26.8mmol，59.3％)。1HNMR(DMSO-d6,400MHz)δ：12.08(s,1H),4.70(s,1H),4.57(s,1H),2.90～2.99(m,1H),2.46～2.30(m,2H),2.25(dt,J＝12.7,3.5Hz,1H),2.15～2.08(m,1H),1.87～1.73(m,3H),1.65(s,3H),1.62(s,1H),1.54(t,J＝11.3Hz,1H),1.48～1.00(m,15H),0.98(s,3H),0.95(s,3H),0.93(s,3H),0.90(s,3H),0.85(s,3H)。
化合物3的合成：在100mL圆底烧瓶中，将化合物2(4.54g，10mmol)溶于CH2Cl2中，0℃滴加草酰氯(12.7g，100mmol)。反应完毕后蒸干溶剂，剩余物加入甲醇加热回流，TLC监测反应完毕后蒸干溶剂，加入乙酸乙酯萃取，水洗，有机相用Na2SO4干燥，柱色谱分离得到白色固体化合物3(3.36g，7.17mmol，71.7％)。1H NMR(CDCl3,400MHz)δ：4.74(s,1H),4.61(s,1H),3.68(s,3H),3.05～2.94(m,1H),2.56～2.32(m,2H),2.31～2.17(m,2H),1.96～1.83(m,3H),1.77～1.66(m,1H),1.69(s,3H),1.65～1.52(m,6H),1.51～1.11(m,13H),1.07(s,3H),1.02(s,3H),0.97(s,3H),0.95(s,3H),0.92(s,3H)。13C NMR(CDCl3,100MHz)δ：218.2,176.6,150.5,109.6,56.5,55.0,51.3,49.9,49.4,47.3,46.9,42.4,40.6,39.6,38.3,36.9,36.9,34.2,33.6,32.1,30.6,29.6,26.6,25.5,21.4,21.0,19.6,19.4,15.9,15.7,14.6。
化合物4的合成：在500mL圆底烧瓶中，加入化合物3(2.54g，5.42mmol)，和135mL四氢呋喃，室温搅拌加入1mol/L的KN(SiMe3)2的四氢呋喃溶液(40mL)，搅拌1h后加入1mol/L三乙胺硼烷(NEt3B)的四氢呋喃溶液(40mL)，继续搅拌1.5h，加入溴丙炔(4mL)。反应完毕后，加入3mol/L的HCl(3.0mL)淬灭反应，用乙酸乙酯萃取三次，合并有机相，将有机相用饱和碳酸氢钠溶液洗两次，Na2SO4干燥，柱色谱分离得到白色固体化合物4(2.32g，4.58mmol，84.5％)。1H NMR(CDCl3,400MHz)δ：4.72(s,1H),4.58(s,1H),3.67(s,3H),3.05～2.94(m,1H),2.91～2.77(m,1H),2.60(ddd,J＝17.1,4.4,2.7Hz,1H),2.33(dd,J＝12.9,5.6Hz,1H),2.29～2.10(m,3H),1.94(t,J＝2.7Hz,1H),1.91～1.83(m,1H),1.79～1.70(m,1H),1.67(s,3H),1.63～1.14(m,14H),1.17～1.01(m,3H),1.12(s,3H),1.06(s,3H),1.04(s,3H),0.98(s,3H),0.94(s,3H)。13C NMR(CDCl3,100MHz)δ：218.2,176.6,150.4,109.7,83.0,69.4,57.3,56.5,51.3,50.1,49.4,48.3,47.0,46.6,42.5,41.2,40.8,38.2,37.4,36.9,34.1,32.1,30.5,29.6,25.4,25.0,21.6,21.2,19.5,19.3,16.1,14.6。
化合物5的合成：在500mL圆底烧瓶中，加入化合物4(2.03g，4.0mmol)、120mL甲醇和硼氢化钠(303mg，8.0mmol)。室温搅拌5h后，加入3mol/L的HCl(60.0mL)，蒸干溶剂用乙酸乙酯萃取三次，合并有机相，将有机相用饱和碳酸氢钠溶液洗两次，将有机相干燥浓缩，柱色谱分离，用石油醚：乙酸乙酯＝20:1做洗脱剂，得到白色固体化合物5(1.67g，3.28mmol，82.1％)。1H NMR(CDCl3,400MHz)δ：4.73(s,1H),4.59(s,1H),3.67(s,3H),3.07～2.93(m,2H),2.47～2.12(m,4H),1.98(t,J＝2.4Hz,1H),1.68(s,3H),1.58(t,J＝11.4Hz,3H),0.98(s,3H),0.97(s,3H),0.92(s,3H),0.86(s,3H),0.78(s,3H)。13C NMR(CDCl3,100MHz)δ：176.6,150.5,109.6,82.9,81.4,69.9,56.5,55.4,51.2,50.4,49.4,46.9,44.8,42.4,40.6,39.1,38.2,37.3,36.9,34.7,34.2,32.1,30.5,29.6,28.3,25.5,22.3,20.9,19.3,18.5,16.9,16.2,15.9,14.7。
化合物6的合成：在25mL圆底烧瓶中，加入化合物5(394mg，0.77mmol)、碘化锂(1.0g，7.5mmol)和DMF(15mL)，回流48h，反应完毕后加入3mol/L的HCl(10mL)，乙酸乙酯萃取三次，合并有机相，将有机相用饱和碳酸氢钠溶液洗两次，将有机相干燥浓缩，用石油醚：乙酸乙酯＝3:1做洗脱剂，得到白色固体化合物6(287mg，0.58mmol，74.9％)。1H NMR(CDCl3,400MHz)δ：4.77-4.71(m,1H),4.63-4.57(m,1H),3.07-2.95(m,2H),2.45-2.30(m,2H),2.27(dt,J＝12.6,2.9Hz,1H),2.24-2.14(m,1H),2.00-1.95(m,2H),1.83(dd,J＝12.8,3.6Hz,1H),1.79-1.69(m,2H),1.69(s,3H),1.66-1.16(m,13H),1.12-1.02(m,1H),0.98(s,6H),0.94(s,3H),0.87(s,3H),0.85-0.80(m,1H),0.78(s,3H),0.76-0.70(m,1H).13C NMR(CDCl3,100MHz)δ180.2,150.3,109.8,82.9,81.5,70.0,56.2,55.4,50.4,49.2,46.9,44.8,42.5,40.7,39.1,38.4,37.3,37.0,34.8,34.2,32.1,30.5,29.6,28.3,25.5,22.4,20.9,19.3,18.5,16.99,16.2,16.0,14.7.
化合物i的合成：将炔基化合物6(0.24mmol)和叠氮基化合物4’-叠氮尿苷(0.2mmol)溶解到2mL的水和叔丁醇(体积比1:1)中，再加入N,N-二异丙基乙胺(DIPEA,50uL,0.3mmol)。室温搅拌15分钟后，再加入乙腈(1mL)的碘化亚铜(4mg,0.02mmol)溶液继续室温搅拌至反应完毕。蒸干溶剂后直接柱层析分离，二氯甲烷/甲醇(20:1-5:1)分离得到白色固体化合物i(108mg,0.137mmol,68.5％)。1H NMR(DMSO-d6,400MHz)δ：11.56(brs,1H),7.94(s,1H),7.84(d,J＝8.0Hz,1H),6.70(t,J＝6.9Hz,1H),6.36(d,J＝5.1Hz,1H),5.99(brs,1H),5.75(d,J＝8.0Hz,1H),5.40(dt,J＝54.5,5.7Hz,1H),4.78(dt,J＝25.9,4.9Hz,1H),4.69(s,1H),4.56(s,1H),4.28-4.02(m,2H),3.60(s,3H),3.21-3.00(m,2H),2.98-2.83(m,1H),2.43(dd,J＝14.7,7.4Hz,1H),2.22-2.05(m,2H),2.04-1.92(m,1H),1.86-1.70(m,2H),1.64(s,3H),1.61-1.16(m,14H),1.15-1.06(m,2H),1.04-0.93(m,1H),1.03(s,3H),1.01(s,3H),0.98(s,3H),0.92(s,3H),0.89(s,3H).13C NMR(DMSO-d6,100MHz)δ：215.6,175.6,162.9,150.2,150.0,144.5,141.2,122.2,109.8,101.8,95.5(d,J＝11.0Hz),94.7(d,J＝192.5Hz),82.2,74.0(d,J＝24.1Hz),60.6,56.6,55.8,51.3,49.2,48.7,47.7,46.6,46.2,42.1,41.1,40.2,37.6,36.9,36.1,33.5,31.4,29.9,29.1,25.7,25.1,24.9,21.2,20.6,18.9,18.8,15.7,15.6,14.3.HRMS(ESI)calcd for C43H60FN5O8[M+H]+794.4504,found794.4500.
实施例2：化合物ii和iii的制备
参考实施例1的方法，制备化合物ii和iii，其理化表征数据如下。
化合物ii,白色固体，收率68.8％。1H NMR(DMSO-d6,400MHz)δ：11.56(s,1H),7.92(s,1H),7.84(d,J＝8.2Hz,1H),6.72(t,J＝7.1Hz,1H),6.31(d,J＝5.6Hz,1H),5.96(t,J＝5.6Hz,1H),5.75(d,J＝8.1Hz,1H),5.41(dt,J＝55.5,6.0Hz,1H),4.77(dt,J＝25.8,5.7Hz,1H),4.68(brs,1H),4.58(d,J＝6.5Hz,1H),4.56(s,1H),4.15(ddd,J＝32.8,12.6,5.5Hz,2H),3.58(s,3H),3.16-3.09(m,1H),2.89(td,J＝10.4,5.1Hz,1H),2.68(dd,J＝10.4,6.7Hz,1H),2.25(dd,J＝14.3,9.5Hz,1H),2.18-2.04(m,2H),1.86-1.72(m,3H),1.64(s,3H),1.62-1.53(m,3H),1.47-1.03(m,14H),0.91(s,3H),0.90(s,3H),0.81(s,3H),0.71(s,3H),0.70(s,3H),0.73-0.63(m,1H),0.49(t,J＝12.6Hz,1H).13C NMR(DMSO-d6,400MHz)δ：175.6,162.9,150.2,150.0,145.0,141.2,122.1,109.8,101.8,94.7(d,J＝192.1Hz),95.3(d,J＝11.0Hz),82.2,80.3,74.0(d,J＝25.2Hz),60.5,55.8,55.0,51.2,49.8,48.7,46.6,44.3,42.0,40.2,38.9,37.6,36.7,36.1,35.5,33.8,31.4,30.0,29.1,28.5,28.5,25.0,20.3,18.9,18.2,16.6,16.6,15.6,14.4.HRMS(ESI)calcd for C43H62FN5O8[M+H]+796.4661,found 796.4656.
化合物iii,白色固体，收率48.8％。1H NMR(DMSO-d6,400MHz)δ:12.03(brs,1H),11.56(s,1H),7.92(s,1H),7.84(d,J＝8.3Hz,1H),6.73(t,J＝7.0Hz,1H),6.30(d,J＝5.6Hz,1H),5.94(t,J＝5.5Hz,1H),5.75(dd,J＝8.1,1.5Hz,1H),5.42(dt,J＝55.4,6.0Hz,1H),4.78(dt,J＝25.8,5.7Hz,1H),4.67(s,1H),4.57(d,J＝6.2Hz,1H),4.55(s,1H),4.16(ddd,J＝31.0,12.3,5.8Hz,2H),3.21-3.08(m,1H),2.99-2.85(m,1H),2.69(dd,J＝9.8,6.3Hz,1H),2.32-2.04(m,3H),1.90-1.71(m,3H),1.68-1.54(m,2H),1.63(s,3H),1.54-1.20(m,11H),1.14-1.01(m,2H),1.01-0.88(m,1H),0.91(s,3H),0.91(s,3H),0.84(s,3H),0.71(s,3H),0.71(s,3H),0.73-0.63(m,1H),0.50(t,J＝12.4Hz,1H).13CNMR(DMSO-d6,100MHz)δ:177.2,162.8,150.2,145.1,141.2,122.2,109.6,101.8,95.3(d,J＝10.9Hz),94.7(d,J＝192.3Hz),82.2(d,J＝16.0Hz),80.3,74.0(d,J＝24.3Hz),60.6,55.4,55.0,49.9,48.5,46.6,44.3,42.0,40.2,38.9,37.5,36.7,36.3,35.5,33.8,31.7,30.0,29.1,28.5,28.5,25.0,20.3,18.9,18.2,16.7,16.6,16.6,15.7,14.3.HRMS(ESI)calcd forC42H60FN5O8[M+H]+782.4504,found 782.4498.
实施例3：化合物iv、v和vi的制备
参考实施例1的方法，制备化合物iv、v和vi，其反应路线和表征数据如下：
化合物iv，白色固体，收率74.8％。1H NMR(CDCl3,400MHz)δ:9.73(s,1H),7.56(s,2H),6.29(t,J＝6.4Hz,1H),5.47-5.34(m,1H),4.72(s,1H),4.58(s,1H),4.45-4.34(m,1H),4.11-3.94(m,2H),3.88-3.74(m,1H),3.67(s,3H),3.24-3.12(m,1H),3.09(dd,J＝14.4,6.9Hz,1H),3.03-2.83(m,3H),2.60(dd,J＝14.4,4.2Hz,1H),2.27-2.08(m,3H),1.94-1.83(m,2H),1.90(s,3H),1.76-1.65(m,1H),1.67(s,3H),1.60-1.51(m,2H),1.48-1.23(m,10H),1.16-1.06(m,3H),1.12(s,3H),1.03(s,3H),1.02(s,3H),0.96(s,3H),0.94(s,3H).13C NMR(CDCl3,100MHz)δ：217.4,176.6,164.1,150.5,150.3,146.8,137.7,122.4,111.0,109.7,87.9,85.2,61.3,58.9,57.5,56.4,51.2,50.0,49.3,48.5,47.9,46.9,42.4,42.2,40.7,38.1,37.6,37.5,36.9,34.0,32.1,30.4,29.5,26.4,25.3,24.9,21.4,21.1,19.2,19.2,16.1,16.0,14.6,12.4.HRMS(ESI)calcd for C44H63N5O7[M+H]+774.4806,found774.4802.
化合物v，白色固体，收率78.3％。.1H NMR(DMSO-d6,400MHz)δ:11.4(s,1H),8.00(s,1H),7.82(brs,1H),6.39(t,J＝6.5Hz,1H),5.35-5.28(m,1H),5.27(t,J＝5.3Hz,1H),4.68(s,1H),4.60-4.52(m,2H),4.17(dt,J＝5.8,3.6Hz,1H),3.74-3.54(m,2H),3.58(s,3H),3.15(dd,J＝14.1,2.3Hz,1H),2.95-2.84(m,1H),2.79-2.58(m,3H),2.26(dd,J＝14.5,9.4Hz,1H),2.16-2.04(m,2H),1.81(s,3H),1.80-1.68(m,3H),1.64(s,3H),1.62-1.50(m,3H),1.50-1.16(m,10H),1.12-0.93(m,3H),0.92(s,3H),0.90(s,3H),0.81(s,3H),0.71(s,3H),0.69(s,3H),0.71-0.62(m,1H),0.51(t,J＝12.6Hz,1H).13C NMR(DMSO-d6,100MHz)δ：175.6,163.7,150.4,150.0,146.1,136.2,122.0,109.8,109.5,84.5,83.8,80.3,60.6,58.7,55.8,55.0,51.2,49.9,48.7,46.6,44.4,42.0,40.2,38.9,37.6,37.0,36.6,36.1,35.6,33.8,31.4,29.9,29.1,28.7,28.5,25.0,20.3,18.9,18.2,16.6,16.6,15.6,14.4,12.3.HRMS(ESI)calcd for C44H65N5O7[M+H]+776.4962,found 776.4959.
化合物vi，白色固体，收率57.3％。1H NMR(DMSO-d6,400MHz)δ:12.06(brs,1H),11.4(s,1H),7.99(s,1H),7.82(d,J＝1.0Hz,1H),6.39(t,J＝6.6Hz,1H),5.35-5.28(m,1H),5.27(t,J＝5.3Hz,1H),4.67(d,J＝1.8Hz,1H),4.56(d,J＝6.6Hz,1H),4.55(s,1H),4.17(dt,J＝5.3,3.3Hz,1H),3.74-3.54(m,2H),3.15(dd,J＝14.3,2.8Hz,1H),2.93(td,J＝10.6,5.1Hz,1H),2.79-2.58(m,3H),2.31-2.04(m,3H),1.81(s,3H),1.80-1.68(m,3H),1.63(s,3H),1.62-1.55(m,2H),1.50(t,J＝11.5Hz,1H),1.46-1.16(m,10H),1.14-1.02(m,2H),0.99-0.90(m,1H),0.92(s,3H),0.90(s,3H),0.84(s,3H),0.71(s,3H),0.69(s,3H),0.71-0.62(m,1H),0.51(t,J＝13.1Hz,1H).13C NMR(DMSO-d6,100MHz)δ：177.2,163.7,150.4,150.3,146.2,136.2,122.1,109.7,109.6,84.5,83.8,80.3,60.7,58.8,55.4,55.0,49.9,48.5,46.6,44.5,42.0,40.3,38.9,37.5,37.0,36.7,36.3,35.6,33.8,31.7,30.0,29.1,28.7,28.5,25.0,20.4,18.9,18.2,16.6,16.6,15.7,14.4,12.3.HRMS(ESI)calcdfor C43H63N5O7[M+H]+762.4806,found 762.4802.
实施例4：生物活性测试
4.1抗癌活性测试
本实验用不同浓度的受试化合物分别作用于上述肿瘤细胞48小时，通过MTT法检测细胞生长抑制率，来检测化合物对不同肿瘤细胞的抑制程度。
实验方法：
将受试溶解于一定体积的DMSO中，配成浓度为10mmol/L的母液4℃保存，使用的时候取母液稀释为一定倍数的溶液。
具体操作步骤如下：
(1)取处于对数生长期的上述肿瘤细胞细胞，离心、重悬，调整细胞悬液密度至8×104cell/mL，接种于96孔培养板中，每孔加入100μL细胞悬液，然后放置细胞培养箱中37℃，5％CO2常规培养。
(2)孵育24h后，显微镜下观察各孔细胞单层贴壁均匀生长，实验组孔内分别加入不同浓度的受试化合物溶液1μL，使化合物终浓度均分别为1.5、3、6.25、12.5、25、50、75、100μmol/L，每个浓度均设4个复孔；同时设空白组(只加入培养基不加细胞悬液)、阴性对照组(只加入细胞悬液)。
(3)放置培养箱培养48h后，每孔加入20μL MTT溶液，在培养箱中继续培养4h。然后小心弃去上层培养基，每孔加入150μl DMSO，至于摇床上37℃恒温震荡10min，使结晶物充分溶解。在酶联免疫检测仪490nm波长下检测各孔吸光度OD值。
(4)计算样品对细胞的抑制作用，公式如下：
抑制率(％)＝(细胞对照孔OD值－给药孔OD值)/(细胞对照孔OD值－空白孔OD值)×100％
根据所计算的抑制率，求出各受试化合物抑制细胞生长的半数抑制浓度IC50值。
表1：受试化合物的IC50值(μmol/L)
由表1可以看出：一定剂量的本发明化合物样品均对癌细胞存在不同程度的抑制作用。
4.2抗HIV活性实验
MT4细胞中的多周期病毒复制
在96孔板中加入各种浓度的化合物，以50％组织细胞感染量/孔的剂量使HIV-1NL4-3 Nanoluc-sec感染MT4细胞(1×105细胞/mL)。HIV-1NL4-3 Nanoluc-sec病毒是使用Not I和Xho I限制酶切位点的质粒(GenBank：AF324493.2)通过插入来自pNL1.3[secNluc](Promega Cat#：N1021)的secNluc序列代替pNL4-3核苷酸8796-8892的Nef序列得到的。通过位点定向诱变将Not I位点引入pNL4-3，而Xho I位点是pNL4-3中的独特的位点。感染后第3天，收集上清液样品，并使用Promega 荧光素酶测定系统测定荧光素酶活性。抗病毒能力定义为将萤光素酶活性降低50％(IC50)的药物浓度。
细胞毒性测定
发光细胞毒性测定法(Promega)测定化合物的细胞毒性。在各种浓度的化合物存在下培养MT4细胞3天。按照制造商提供的方案测定化合物的细胞毒性。50％细胞毒性浓度(CC50)定义为引起细胞活力降低50％的浓度。
表2受试化合物的抗HIV活性
以上，对本发明的实施方式进行了说明。但是，本发明不限定于上述实施方式。凡在本发明的精神和原则之内，所做的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (6)
1.白桦脂酸衍生物、其药学上可接受的盐或互变异构体，其特征在于，所述的白桦脂酸衍生物选自如下化合物中的一种：
。
2.权利要求1所述白桦脂酸衍生物的制备方法，包括将式（1）化合物与式（2）化合物反应，得到所述的白桦脂酸衍生物：
，
其中，X为O；
-Het1-Het2选自，其中Z为O，/>为双键，R为H，R1为甲基，R2为OH；
或，-Het1-Het2选自其中：
Z为O，为双键，R为甲基，R1为甲基；或
Z一起为/>，R为甲基，R1为甲基。
3.根据权利要求2所述的制备方法，其特征在于，所述反应在溶剂中进行；
所述溶剂为水与有机溶剂的混合溶剂；
所述有机溶剂选自甲醇、乙醇、异丙醇、正丁醇、叔丁醇、四氢呋喃、二氧六环、N,N-二甲基甲酰胺。
4.根据权利要求3所述的制备方法，其特征在于，所述水与有机溶剂的体积比为1:0.2-5；
所述反应在催化剂存在下进行，所述催化剂为Cu和CuSO4的组合、CuCl、CuI；
所述反应中化合物1与催化剂的摩尔比为1:0.1-1；
所述反应中化合物1与化合物2的摩尔比为1:0.5-2。
5.一种药物组合物，其包含治疗有效量的权利要求1所述的白桦脂酸衍生物、其药学上可接受的盐或互变异构体。
6.权利要求1所述的白桦脂酸衍生物，其药学上可接受的盐或互变异构体在制备药物中的用途，其中所述药物用于抑制癌细胞生长，所述癌细胞选自下列的细胞：Hela、Siha、A549、MCF-7、HEPG2、SK-BR-3。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010785694.XA CN114057823B (zh) | 2020-08-06 | 2020-08-06 | 白桦脂酸衍生物，其制备方法、药物组合物和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010785694.XA CN114057823B (zh) | 2020-08-06 | 2020-08-06 | 白桦脂酸衍生物，其制备方法、药物组合物和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114057823A CN114057823A (zh) | 2022-02-18 |
| CN114057823B true CN114057823B (zh) | 2024-01-30 |
Family
ID=80232524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010785694.XA Active CN114057823B (zh) | 2020-08-06 | 2020-08-06 | 白桦脂酸衍生物，其制备方法、药物组合物和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114057823B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117327140B (zh) * | 2023-11-24 | 2024-03-12 | 潍坊赛宝工业技术研究院有限公司 | 一种具备抑制细菌用途的白桦脂酸衍生物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108727460A (zh) * | 2018-05-19 | 2018-11-02 | 河南省科学院高新技术研究中心 | 白桦脂酮酸衍生物及其合成方法和应用 |
| CN112979743A (zh) * | 2019-12-02 | 2021-06-18 | 河南省医药科学研究院 | 白桦脂酸衍生物及其应用 |
| CN113912663A (zh) * | 2020-07-07 | 2022-01-11 | 河南省生殖健康科学技术研究院(河南省出生缺陷干预工程技术研究中心) | 白桦脂酸衍生物，其制备方法、药物组合物和应用 |
-
2020
- 2020-08-06 CN CN202010785694.XA patent/CN114057823B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108727460A (zh) * | 2018-05-19 | 2018-11-02 | 河南省科学院高新技术研究中心 | 白桦脂酮酸衍生物及其合成方法和应用 |
| CN112979743A (zh) * | 2019-12-02 | 2021-06-18 | 河南省医药科学研究院 | 白桦脂酸衍生物及其应用 |
| CN113912663A (zh) * | 2020-07-07 | 2022-01-11 | 河南省生殖健康科学技术研究院(河南省出生缺陷干预工程技术研究中心) | 白桦脂酸衍生物，其制备方法、药物组合物和应用 |
Non-Patent Citations (3)
| Title |
|---|
| Anti-AIDS agents 88. Anti-HIV conjugates of betulin and betulinic acid with AZT prepared via click chemistry;Ibrahim D. Bori等;《Tetrahedron Letters》;第53卷;第1987-1989页 * |
| Click chemistry-assisted synthesis of novel C-2 triazole-linked betulinic acid conjugates with azidothymidine as potential anti-HIV agents;Spivak, Anna Yu.等;《ARKIVOC》(第7期);第5页方案3、第13页第3段 * |
| Spivak, Anna Yu.等.Click chemistry-assisted synthesis of novel C-2 triazole-linked betulinic acid conjugates with azidothymidine as potential anti-HIV agents.《ARKIVOC》.2018,(第7期),第5页方案3、第13页第3段. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114057823A (zh) | 2022-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2751602T3 (es) | Compuestos diaza y triaza tricíclicos sustituidos con (1-fluoro-ciclohex-1-il)-etilo como antagonistas de la indol-amina-2,3-dioxigenasa (ido) para el tratamiento del cáncer | |
| CN113912663B (zh) | 白桦脂酸衍生物，其制备方法、药物组合物和应用 | |
| JP2020532585A (ja) | インターフェロン遺伝子刺激因子調節薬としての環状ジヌクレオチド | |
| JP7374496B2 (ja) | Ｂｃｌ－２タンパク質を阻害するためのＮ－ベンゼンスルホニルベンズアミド系化合物、その組成物および使用 | |
| WO2017152706A1 (zh) | 吡啶胺基嘧啶衍生物的盐及其制备方法和应用 | |
| CN109851638B (zh) | 取代的二氨基嘧啶化合物 | |
| WO2017152707A1 (zh) | 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用 | |
| CN109384712B (zh) | 靶向nk1受体拮抗剂及其在化疗所致恶心、呕吐治疗中的应用 | |
| CN114008028A (zh) | 抑制癌细胞生长的嘧啶衍生物及其医药用途 | |
| CN114057823B (zh) | 白桦脂酸衍生物，其制备方法、药物组合物和应用 | |
| CN109369721B (zh) | 用于抑制激酶活性的芳基磷氧化物 | |
| CN113402543B (zh) | 丁苯酞开环衍生物及其制备方法和用途 | |
| WO2020001592A1 (zh) | 二氢嘧啶衍生物及其用途 | |
| CN115844903B (zh) | 白桦醇衍生物在制备抑制细菌药物中的用途 | |
| CN115894600A (zh) | 别白桦醇衍生物及其制备方法、药物组合物和应用 | |
| WO2022223020A1 (zh) | 靶向活化与失活态kras g12d的抑制剂 | |
| WO2019228330A1 (zh) | 取代的苯并[d]咪唑类化合物及其药物组合物 | |
| CN111925313B (zh) | 具有pde4抑制活性的化合物、制备方法、组合物及用途 | |
| WO2019001307A1 (zh) | 一种酰胺类化合物及包含该化合物的组合物及其用途 | |
| CN113831342B (zh) | 一种酮咯酸衍生物、药物组合物及其制备方法和应用 | |
| TW202227406A (zh) | Ssao抑制劑之多晶型 | |
| US8981114B2 (en) | Derivatives of 1-(substituted sulfonyl)-2-aminoimidazoline as antitumor and antiproliferative agents | |
| WO2017097113A1 (zh) | 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物 | |
| UA52661C2 (uk) | Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти | |
| CN117327140B (zh) | 一种具备抑制细菌用途的白桦脂酸衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20231213 Address after: 264200. About 180 meters west of the intersection of Hexing Road and Huanwan West Road in Huancui District, Weihai City, Shandong Province, China. Electronic Information Product Testing and Testing Center of the Ministry of Industry and Information Technology Applicant after: Weihai Saibao Industrial Information Technology Research Institute Co.,Ltd. Applicant after: Henan Aipu Bolai Biotechnology Co.,Ltd. Applicant after: HIGH & NEW TECHNOLOGY RESEARCH CENTER, HENAN ACADEMY OF SCIENCES Address before: 450014 No. 26, Jingwu Road, Jinshui District, Zhengzhou City, Henan Province Applicant before: Henan Institute of reproductive health science and Technology (Henan birth defect intervention Engineering Technology Research Center) Applicant before: HIGH & NEW TECHNOLOGY RESEARCH CENTER, HENAN ACADEMY OF SCIENCES |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |